One year after the launch of the partnership between Penn and Johnson & Johnson Innovation, the Pennovation Center celebrated the early successes of this innovative program.
During the JPOD @ 365 celebration, representatives from six Philadelphia health and biotechnology start-ups shared how partnering with Johnson & Johnson Innovation impacted their company’s growth over the past year. The panel on Impact, moderated by Marion Leary (far right), included (from left) Siva Nadarajah, Sasha Schrode, and Brandon Kao. (Image: Helm Creative Studio)
A year after the official launch of JPOD @ Philadelphia, the Pennovation Center celebrated the first 365 days of a successful partnership between Penn and Johnson & Johnson Innovation JLABS. To mark the occasion, nearly 100 entrepreneurs, businesspeople, and members of the Penn community came together to hear stories and milestones from its cohort of 15 companies.
As a full-service business and technology incubator housed at the Pennovation Center, JPOD @ Philadelphia’s goal is to identify and accelerate the development of early-stage health care solutions from the Philadelphia region’s life science ecosystem. JPOD @ Philadelphia is part of the JLABS global network of open innovation environments, which have incubated more than 600 companies that aim to advance biotech, pharmaceutical, medical-device, consumer and health-tech programs around the world.
Pennovation Center's first floor benches were decked out for the one year celebration of JPOD @ Philadelphia. (Image: Helm Creative Studio)
Welcoming attendees was Nicholas Pachuda, vice president of orthopedics innovation for Johnson & Johnson, who said he was already encouraged by the success stories seen in JPOD @ Philadelphia’s first year. With other startups becoming more interested in the greater Philadelphia area thanks to its network of clinicians, scientists, engineers, business leaders, investors, entrepreneurs, and companies, Pachuda is also looking forward to seeing where the incubator’s momentum takes JPOD @ Philadelphia next.
“It’s a tribute to the ingredients for success that are here in Philly,” said Pachuda. “Philly is becoming a destination city for innovation, and the ability for JPOD @ Philadelphia to drive that regional ecosystem is exciting for us to be a part of.”
The JPOD @ Philadelphia cohort includes startups working on technologies that aim to address significant unmet patient and consumer needs in medical devices, pharmaceuticals, and consumer and health technologies. Companies at the Pennovation Center are focused on technologies ranging from 3D tissue printing, wearable biosensors, CAR T cell therapies, nanoparticle drug delivery, and remote patient monitoring. During the celebration, representatives from six of the JPOD @ Philadelphia companies spoke during two panels to highlight how their partnership with Johnson & Johnson Innovation had impacted their company’s growth during the past year.
The panel on innovation was led by Glory Durham, associate director of Penn Health-Tech, which serves as a hub for health technology innovators at Penn. Panel speakers included Ilene Busch-Vishniac from Sonavi Labs, Dan Gurra from Algometrx, and Joshua Buser from Chip Diagnostics, a Philadelphia-based device company based on research from the lab of Penn’s David Issadore. Chip Diagnostics was the awardee of the JPOD @ Philadelphia QuickFire Challenge Award earlier this year.
When asked about the impact of joining the JPOD @ Philadelphia team, the panelists shared examples of how working with their company’s JPALS helped launch each of their businesses. Buser said that the partnership helped Chip Diagnostics gain key insights on how to approach problems and how to position their technology to make an impact, both medically and commercially, which they wouldn’t have been able to access to without the JPOD @ Philadelphia partnership.
Glory Durham introduces the innovation panelists to a crowd of entrepreneurs, businesspeople, and members of the Penn community at Pennovation Center. (Image: Helm Creative Studio)
“Johnson & Johnson Innovation has a farther than 30,000-foot view,” said Buser about the company’s ability to look ahead, especially within the realm of medical diagnostics. “It’s given us really valuable information on how to mitigate risks that come with being in this space.”
The impact panel was moderated by Marion Leary, director of innovation at Penn Nursing who has worked with Johnson & Johnson Innovation on numerous initiatives, including the QuickFire Challenge Award and an upcoming nursing hackathon. Panelists included Siva Nadarajah of Jogo Health, as well as representatives from two companies with strong Penn ties: Sasha Schrode of Verix Health formerly Greppo Technologies, a startup from Mark Yim of the GRASP lab incubated by the Penn Center for Innovation via its venture group, PCIV, and Brandon Kao of Avisi Technologies, one of the winners of Penn President Amy Gutmann’s 2018 President’s Innovation Prize.
The panelists agreed that being able to work at Pennovation Center alongside other startup companies and Philadelphia-area entrepreneurs was supportive and made their work feel less isolated and challenging. “Sharing investor contacts and best practices, all with people who are going through same thing as us, has been very helpful,” said Kao.
The Penn Center for Innovation’s Laurie Actman closed the day, saying she is looking forward to seeing how JPOD @ Philadelphia continues to grow over the next year. “Having a partner like Johnson & Johnson Innovation and JLABS was our dream, and it really is amazing just one year later to see everything they’ve brought to help us grow this ecosystem,” said Actman.
Nanoparticle blueprints reveal path to smarter medicines
New research involving Penn Engineering shows detailed variation in lipid nanoparticle size, shape, and internal structure, and finds that such factors correlate with how well they deliver therapeutic cargo to a particular destination.
A generous gift from alumni Glenn and Amanda Fuhrman brings the work of internationally acclaimed artist Jaume Plensa to the University of Pennsylvania. The latest addition to the Penn Art Collection expands Philadelphia's public art.
A massive chunk of ice, a new laser, and new information on sea-level rise
For nearly a decade, Leigh Stearns and collaborators aimed a laser scanner system at Greenland’s Helheim Glacier. Their long-running survey reveals that Helheim’s massive calving events don’t behave the way scientists once thought, reframing how ice loss contributes to sea-level rise.
